These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Pedersen SS; Jensen T; Osterhammel D; Osterhammel P Antimicrob Agents Chemother; 1987 Apr; 31(4):594-9. PubMed ID: 3606063 [TBL] [Abstract][Full Text] [Related]
32. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis. McCarty JM; Tilden SJ; Black P; Craft JC; Blumer J; Waring W; Halsey NA Pediatr Pulmonol; 1988; 4(4):201-4. PubMed ID: 3393383 [TBL] [Abstract][Full Text] [Related]
33. Treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis patients with ceftazidime and tobramycin. Heilesen AM; Permin H; Koch C; Høiby N Scand J Infect Dis; 1983; 15(3):271-6. PubMed ID: 6417770 [TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients. van Koningsbruggen-Rietschel S; Heuer HE; Merkel N; Posselt HG; Staab D; Sieder C; Ziegler J; Krippner F; Rietschel E J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719 [TBL] [Abstract][Full Text] [Related]
35. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. Powell SH; Thompson WL; Luthe MA; Stern RC; Grossniklaus DA; Bloxham DD; Groden DL; Jacobs MR; DiScenna AO; Cash HA; Klinger JD J Infect Dis; 1983 May; 147(5):918-32. PubMed ID: 6860416 [TBL] [Abstract][Full Text] [Related]
36. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Vic P; Ategbo S; Turck D; Husson MO; Launay V; Loeuille GA; Sardet A; Deschildre A; Druon D; Arrouet-Lagande C Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009 [TBL] [Abstract][Full Text] [Related]
37. Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin. Conway SP; Miller MG; Ramsden C; Littlewood JM Acta Paediatr Scand; 1985 Jan; 74(1):107-13. PubMed ID: 3885674 [TBL] [Abstract][Full Text] [Related]
38. Tobramycin elimination rate change from first to later doses in older cystic fibrosis patients. Horner GW; Stempel DA Drug Intell Clin Pharm; 1987 Mar; 21(3):276-8. PubMed ID: 3569027 [TBL] [Abstract][Full Text] [Related]
39. Aminoglycoside dosage in pediatric patients:considerations regarding pharmacokinetic-based dose adjustment in patients requiring high versus low dose therapy. Leff RD; Roberts RJ Dev Pharmacol Ther; 1981; 3(4):242-50. PubMed ID: 7344881 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. Massie J; Cranswick N J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]